Showing results (61-70 of 300) with videos related to
Sort By:
Pageof 30
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|October 4, 2019
[Non erythropoietic effects of Erythropoietin]Chiara Guglielmo, Chiara Cantarelli, Andrea Angeletti, et al.Pediatric Nephrology (Berlin, Germany)|October 6, 2016
Achieving remission of proteinuria in childhood CKDPiero Ruggenenti, Paolo Cravedi, Antonietta Chianca, et al.Frontiers in Immunology|January 11, 2020
Effects of Antirejection Drugs on Innate Immune Cells After Kidney TransplantationGianluigi Zaza, Jeremy Leventhal, Lorenzo Signorini, et al.Frontiers in Medicine|February 8, 2021
Complement, a Therapeutic Target in Diabetic Kidney DiseaseKelly Budge, Sergio Dellepiane, Samuel Mon-Wei Yu, et al.Transplantation|May 21, 2026
The Kidney-immune Axis: How Erythropoietin Regulates Tolerance and RejectionChiara Cantarelli, Sofia Bin, Andrea Angeletti, et al.American Journal of Physiology. Renal Physiology|July 7, 2026
Deletion of decay-accelerating factor in kidney tubular cells mitigates kidney fibrosis in aristolochic acid nephropathySamuel Mon-Wei Yu, Emily King, Sari Khleif, et al.Transplantation|January 3, 2025
Where Are All the Clinical Trials for Chronic Rejection?Paolo Cravedi, Umberto Maggiore, Paolo Molinari, et al.Current Diabetes Reviews|March 29, 2011
Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectivesManuela Abbate, Paolo Cravedi, Ilian Iliev, et al.Frontiers in Medicine|July 28, 2017
Complement in Non-Antibody-Mediated Kidney DiseasesAndrea Angeletti, Joselyn Reyes-Bahamonde, Paolo Cravedi, et al.Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?Paolo Cravedi, Varusca Brusegan, Piero Ruggenenti, et al.Pageof 30